AlphaFold predicted structure
CDK19 · Q9BWU1

Mean pLDDT
76.6/ 100
Confident
502 residues
Confidence breakdown
- Very high(≥ 90)56%
- Confident(70–90)10%
- Low(50–70)8%
- Very low(< 50)27%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
cyclin dependent kinase 19
Annotations refreshed 9 hours ago.
Diagnostic Grade (Green)
DDG2P
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownEarly onset or syndromic epilepsy
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownIntellectual disability
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinteddevelopmental and epileptic encephalopathy, 87
hereditary disease
undetermined early-onset epileptic encephalopathy
diabetes mellitus
alcohol drinking
urolithiasis
risk-taking behaviour
placental abruption
bronchial disorder
self-injurious ideation
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Cyclin-dependent kinase 19
Component of the Mediator complex, a transcriptional coactivator required for regulated expression of nearly all RNA polymerase II-dependent genes. Acts as a molecular bridge between gene-specific regulatory proteins and the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters through direct interactions with transcriptional regulators and serves as a scaffold for assembly of the pre-initiation complex with RNA polymerase II and general transcription factors. Contributes to phosphorylation of transcription factors and other substrates, including RNA polymerase II and the Notch1 intracellular domain (ICN1), thereby modulating gene expression programs (PubMed:25344755, PubMed:28855340, PubMed:29440396). Plays a role together with CDK8 in normal macrophage differentiation (By similarity)
CDK19 · Q9BWU1

Mean pLDDT
76.6/ 100
Confident
502 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0